Taro Pharmaceutical approve Merger with Sun Pharma

Taro Pharmaceutical’s merger agreement with Sun Pharmaceutical was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting. Upon completion of the merger, currently expected to close in approximately 35 days, Taro will become a privately held company wholly owned by Sun Pharma and soon after its shares will be de-listed from the NYSE.